INTRODUCTION {#sec1-1}
============

The workup of a biliary stricture, pancreatic cyst or solid mass requires a carefully orchestrated sequence of clinical and imaging studies which may be followed by cytologic investigation. The current document describes the clinical work-up along with imaging studies as recommended by the Papanicolaou Society of Cytopathology. Recommendations are made for the appropriate use of bile duct brushing cytology obtained via endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS)-fine-needle aspiration (FNA) cytology of mass lesions in the pancreas. Prebrushing and FNA requirements are discussed including consent forms and information to be included in the requisition form for optimal cytologic evaluation of pancreatic and biliary tract specimens.

PRESENTATION AND CLINICAL EVALUATION {#sec1-2}
====================================

A variety of clinical and laboratory features are associated with malignancy of the biliary tract or pancreas. Newly diagnosed late onset diabetes mellitus or unexplained acute pancreatitis in an older individual require workup, which often includes exclusion of pancreatic carcinoma.\[[@ref1]\] Similarly, the development of jaundice, pruritus or cholestasis not explained by underlying liver or gallbladder disease or choledocholithiasis should initiate an evaluation for neoplasia of the hepaticobiliary tract.\[[@ref1][@ref2][@ref3]\] In addition to the above, clinical investigation and imaging studies may be initiated for a variety of reasons including abdominal pain that radiates to the back, anorexia, weight loss, new onset diabetes, steatorrhea, the presence of newly discovered metastatic disease or abnormal liver enzymes. Laboratory and imaging studies play an important role in the evaluation of patients with pancreaticobiliary lesions.

Patients with suspected neoplasia of the pancreaticobiliary tract should receive:

A thorough history and physical examination including identifying risk factors for malignant causes and for benign explanations for a stricture or cyst (e.g., chronic pancreatitis, primary sclerosing cholangitis (PSC)/inflammatory bowel disease (IBD), autoimmune disease, etc.)Laboratory studies to detect elevations of serum bilirubin and alkaline phosphatase as well as other liver chemistriesSelective use of serum tumor markers including CA19-9 and carcinoembryonic antigen (CEA)\[[@ref4][@ref5][@ref6]\]Imaging studiesSelective use of serum IgG4 when autoimmune diseases are suspected.

IMAGING STUDIES {#sec1-3}
===============

Imaging modalities used in evaluating patients with clinically suspected pancreaticobiliary neoplasia include abdominal ultrasound (AUS) selective use of computerized tomography (CT), ERCP, EUS, and/or magnetic resonance imaging (MRI). When used, MRI may include MR cholangiopancreatography (MRCP) and occasionally, MR angiography (MRA).\[[@ref1][@ref2][@ref3]\] Positron emission tomography-CT is recommended for staging pancreatic cancer if curative surgery is contemplated. It is not currently recommended for diagnosis.

AUS is the least invasive and lowest-cost imaging technique available for evaluation of obstructive jaundice and biliary obstruction by demonstration of biliary duct dilatation when taking into consideration the patient\'s age and history of prior cholecystectomy (both of which can affect ductal diameter). It may also disclose obvious liver metastases. transcutaneous ultrasound (TUS) is operator dependent and has a relatively poor sensitivity for detecting small neoplasms within the pancreatic head.\[[@ref2][@ref3]\] TUS can only see the pancreas in a limited manner, usually due to intervening ultrasound-attenuating abdominal wall fat, the depth of penetration to see the retroperitoneum and/or overlapping gas-filled stomach or loops of bowel. Recent advances in ultrasound technology including color power Doppler ultrasonography, ultrasonographic angiography, contrast harmonic imaging and three-dimensional ultrasonography may improve the sensitivity and specificity of the ultrasound technique.\[[@ref7][@ref8][@ref9][@ref10][@ref11][@ref12][@ref13]\]

Multi-phase CT scanning of the abdomen utilizing fine cuts through the pancreas with contrast enhancement ("pancreas protocol" CT scanning) is more sensitive and specific than AUS for detecting biliary obstruction, and has the ability to determine the site and cause of obstruction. CT is strongly recommended as the primary modality for evaluating patients with suspected malignant biliary obstruction, both for diagnosis and for staging. It also allows detection of liver metastases and invasion of vascular structures as well as potential lymph node involvement.\[[@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\] Multidetector CT (MDCT) may improve accuracy above that obtainable by helical CT. New CT techniques may further increase the sensitivity of CT for pancreatic neoplasia.\[[@ref25][@ref26][@ref27][@ref28]\] MDCT relies heavily on hypoperfusion seen in many adenocarcinomas, and mass effect. Several studies have more recently shown that smaller lesions, on well-perfused tumors can have a modest miss-rate with CT.

If CT findings are consistent with resectable pancreatic carcinoma and the patient is felt to be otherwise an operative candidate, the patient may be referred directly for surgery without further imaging or diagnostic testing, although this clinical situation is rarely encountered. In addition, this approach risks inappropriate surgery for focal pancreatitis (including autoimmune pancreatitis) or lymphoma. Transabdominal or CT guided biopsy of the pancreatic mass may be requested when endoscopic techniques are not readily available, but had a lower performance in a randomized trial.\[[@ref45]\]

When CT scanning reveals definitive evidence of unresectability for pancreatic or biliary tract cancer or if the patient is either a non-operative candidate due to comorbidities or in cases where surgery is planned but delayed (i.e., in patients undergoing neoadjuvant therapy, patients needing more involved evaluation and/or stabilization of other medical issues, etc.), the placement of a biliary stent is typically performed through ERCP for palliation, or to reduce cholestasis to allow adjuvant therapy.

In recent times, neoadjuvant chemotherapy and/or radiation are being utilized in potentially resectable or borderline resectable patients and usually requires a definitive preoperative tissue diagnosis. Transabdominal CT or ultrasound biopsy of metastatic disease may be sufficient; in nonmetastatic disease, EUS-guided FNA is a higher yield maneuver and may be obtained of either the primary site or a metastatic site reachable with EUS. EUS is now the procedure of choice for evaluating and sampling pancreatic masses at many institutions.

Multiple MRI techniques exist for evaluation of the pancreas for neoplastic disease. These include MRI, MRCP, or MRA. Traditional abdominal MRI appears to be a highly accurate modality for staging pancreatic carcinoma but does not appear to be more specific or sensitive than CT.\[[@ref29][@ref30][@ref31]\] Modifications of the MRI technique such as MRCP and MRA may improve sensitivity and specificity and may be useful for vascatar staging.\[[@ref32][@ref33][@ref34][@ref35]\] MRCP provides much better ductal imaging, illustrating the level and cause of the obstruction more reliably than CT, but in determination of benign versus malignant strictures it has weaker performance. It is also more reliable than CT at differentiating solid versus cystic lesions in the pancreas and determining morphology of the cyst and communication with the pancreatic duct. It is weaker at detecting calcifications than CT, which may point to a benign explanation for the stricture or cyst.

DIAGNOSTIC WORK-UP FOR CYSTS OF THE PANCREAS {#sec1-4}
============================================

The most important determination in the investigation of a pancreatic cyst is whether the cyst is mucinous (premalignant) or nonmucinous (serous, developmental and inflammatory).

This distinction by preoperative imaging has been disappointing, but imaging classification systems have been proposed.\[[@ref36]\] Small incidental cysts can usually be managed expectantly.\[[@ref37]\] Serous cystadenomas may have characteristic imaging and clinical features allowing their recognition without further investigation.\[[@ref38]\] Such neoplasms demonstrate a microcystic \"honeycomb\" appearance with a central scar. CT scans are frequently the first test used to evaluate a pancreatic cyst. Endoscopic retrograde pancreatography and EUS can be used if further evaluation is deemed necessary.\[[@ref38]\]

A multidisciplinary conference held at Sendai, Japan in 2005 led to published guidelines in 2006 (the \"Sendai guidelines\"), which established algorithmic protocols for the workup and management of patients with pancreatic neoplastic mucinous cysts.\[[@ref39][@ref40]\] These guidelines were updated in 2010, and published in 2012 (the 2012 guidelines)\[[@ref41]\] \[[Figure 1](#F1){ref-type="fig"}\]. The guidelines base management primarily on clinical and imaging findings with conservative management of small cysts (\<3 cm) occurring in patients without high-risk clinical or imaging findings.
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Patients considered at high-risk for malignancy are those with obstructive jaundice and a cystic lesion in the head of the pancreas, an enhancing solid component within the cyst or a main pancreatic duct ≥10 mm in diameter. These patients are triaged to surgery without preoperative tissue confirmation. If these high-risk features are absent, the patient should be further evaluated for the presence of pancreatitis or worrisome imaging features.

Worrisome imaging features warranting endoscopic ultrasound and consideration of biopsy include a cyst equal to or \>3 cm in diameter, thickened/enhancing cyst wall, a main pancreatic duct 5-9 mm in diameter, a nonenhancing mural nodule, or an abrupt change in the caliber of the main pancreatic duct with distal pancreatic atrophy. Patients with pancreatitis should also be referred for endoscopy. When EUS discloses a definitive mural nodule, a main duct with features suspicious for involvement by the cystic lesion or cytology suspicious or positive for malignancy, the patient should be referred for surgery.

In the absence of high-risk and worrisome features, further management depends on the size of the cystic lesion. Cysts under 1 cm in size should undergo CT/MRI re-examination in 2-3 years. Cysts between 1 and 2 cm in size should have yearly CT/MRI examinations for 2 consecutive years if no significant change is noted, the interval can be lengthened. Patients with cysts between 2 and 3 cm in maximum dimension should undergo EUS examination in 3-6 months. Then have repeat MRI examinations at lengthened intervals alternating with EUS as appropriate. Young fit patients may be considered for surgery. Patients whose cysts are over 3 cm in size should undergo repeat MRI examinations alternating with EUS every 3-6 months. Surgery should be strongly considered as an alternative strategy in young fit patients.

ENDOSCOPIC DIAGNOSTIC TECHNIQUES {#sec1-5}
================================

When EUS is available, it should be used for preoperative staging in patients with suspected pancreatic carcinoma or cancer of the biliary tract. In addition, in low to moderate suspicion cases (dilated ducts or unexplained weight loss), it has high negative predictive value. EUS is particularly useful when CT or MR findings are equivocal, in CT-resectable disease to screen for subtle vascular involvement (especially in borderline surgical candidates), or when unresectable disease is suspected and a tissue diagnosis is needed.\[[@ref42]\] EUS demonstrates significant advantages over CT and MR in establishing the presence of vascular invasion.\[[@ref43][@ref44][@ref45][@ref46]\] EUS appears to be complementary to CT, but EUS appears to be superior for detecting small masses, evaluating for tumor involvement of the superior mesenteric vein and the portal vein and detecting lymph node metastases.\[[@ref43][@ref44][@ref45][@ref46]\] The overall staging accuracy of EUS for pancreatic adenocarcinoma is between 90% and 100%. When compared with CT in this population, EUS has a higher sensitivity for tumor detection. For small (\<16 mm) pancreatic masses, the sensitivity of EUS for tumor detection approaches 100%, compared with 66% using MDCT. Accuracy for resectability, as determined by EUS, is 88-100%.\[[@ref44][@ref45]\] CT appears superior to EUS when evaluating the SMA as EUS can only see this vessel for a short distance beyond its origin, and for establishing the presence of absence of distant metastases.\[[@ref43][@ref44][@ref45][@ref46]\] Adjuncts to EUS, such as elastography and contrast harmonic imaging, are promising to improve performance in selected cases.

A key advantage of EUS is that EUS-guided FNA can be performed as an integral part of EUS examination. This allows definitive tissue acquisition and rapid diagnosis. When EUS suggests resectability, EUS-guided biopsy may not be necessary prior to definitive resection. However, in many institutions all solid pancreatic masses are aspirated prior to surgery (to rule out lymphoma, autoimmune/focal pancreatitis and assess for other types of cancer beyond adenocarcinoma). The requirement for tissue diagnosis in this setting remains controversial. FNA of the mass does have some advantages in that it may establish diagnoses other than primary pancreatic adenocarcinoma and allows for preoperative patient counseling. Many patients in the current era also undergo neoadjuvant therapy preoperatively as well and in general, most medical and radiation oncologists will not treat a patient without a definitive tissue diagnosis. It should be kept in mind that preoperative EUS-guided FNA, while overwhelmingly safe and effective, has a small risk of complications including pancreatitis, infection of upstream obstructed ducts and hemorrhage. The potential for needle track tumor implantation is felt to be extremely small, but still possible and essentially restricted to the body and tail masses sampled with transgastric FNA (since the needle tracks site is resected when transduodenal FNA is followed by a Whipple).\[[@ref47]\]

The evaluation of cystic lesions of the pancreas has historically been a clinical challenge. It is often difficult to identify the type of cystic lesion present based on cross-sectional imaging alone. Furthermore, CT is not particularly helpful in the assessment of the potential malignant character of cysts. MRCP is more helpful at determining the presence of solid components and ductal communication suspicious of intraductal papillary mucinous neoplasm, but small solid components, calcifications and septations may be missed. Some lesions, such as serous cystadenomas, may have a typical appearance that can be identified on cross sectional imaging, but in most cases, further evaluation is needed.

In recent years, it has become clear that cyst fluid analysis may be more helpful than imaging morphology in many cases. Due to the difficulty in assessment of cystic lesions by cross sectional imaging and the ease with which pancreatic cyst fluid can be obtained via EUS, the threshold for cyst aspiration by EUS is very low. While cystic lesions as small as 5-6 mm can be successfully aspirated under EUS, most endoscopists do not perform FNA for cystic lesions under 1-1.5 cm due to the limited amount of fluid/cellular material available for analysis. Cysts \>1-1.5 cm in size are commonly aspirated.\[[@ref48]\] The above criteria apply in the absence of pancreatitis.

A prior history of pancreatitis may or may not prompt a cyst evaluation if there is a strong suspicion that a cystic lesion is a pseudocyst (especially if antecedent imaging obtained before the episode of pancreatitis failed to show the lesion) the lesions may be followed by serial imaging. Pseudocysts obviously arising in acute pancreatitis are not generally aspirated, for many reasons, including low-yield of finding another diagnosis, high overlap of CA19-9 in pseudocysts versus mucinous lesions, and the higher chance of infection in the presence of thick fluid, debris, and necrosis. If there is concern that a cystic lesion may have led to an episode of pancreatitis, EUS with FNA is often warranted.

While all care should be individualized, worrisome signs on EUS of cystic lesions include a size \>2 cm, intracystic nodularity or an associated solid component or thick wall. Pain, pancreatic duct dilatation, jaundice and weight loss also may increase the chance of a malignant cause, although many of these features can be present in chronic pancreatitis. Thus, patients presenting with cystic lesions larger than 2 cm, especially without a history of pancreatitis, pancreatic or bile duct enlargement and/or weight loss should be strongly considered for EUS with FNA.\[[@ref48][@ref49]\]

ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY {#sec1-6}
==============================================

Although years ago, ERCP was felt to be a gold standard for cystic lesions of the pancreas, and evaluation of biliary strictures or a \"double duct sign\", EUS and MRCP have replaced it for many of these indications, avoiding its risks, particularly pancreatitis, and infection of cysts with contrast. It is now only rarely used as a primary tool for establishing the diagnosis of pancreatic adenocarcinoma or workup of pancreatic cysts. Currently, ERCP is the most useful clinically for providing relief of obstructive jaundice by either plastic or metal biliary stent placement. Brush cytology (mono-sampling) from biliary strictures or, to a lesser extent, pancreatic duct strictures, is still widely performed but has a much lower yield than EUS FNA.

DIAGNOSTIC TECHNIQUES FOR SUSPECTED CHOLANGIOCARCINOMA {#sec1-7}
======================================================

EUS has not been shown to be superior to other imaging and sampling techniques for identification of cholangiocarcinoma. EUS identification of cholangiocarcinoma is often technically difficult even for experienced endosonographers, for many reasons. Early cholangiocarcinoma can be laterally spreading along the duct, with minimal \"mass\" or wall thickening. FNA of a thin-walled mass has low yield. Sizable tumors at the hilum have good yield with trans-bulb FNA of either the mass or periportal lymph nodes. Tumors above the hilum are not generally evaluable with EUS.\[[@ref50]\] Intraductal ultrasonography performed at the time of ERCP may add additional information in patients suspected of pancreaticobiliary malignancies especially cholangiocarcinomas, but performance characteristics and accuracy for benign versus malignant strictures appear poor.

POSTIMAGING STUDIES {#sec1-8}
===================

Following studies establishing imaging diagnosis of pancreatic and/or pancreaticobiliary malignancy, some clinicians may desire tissue confirmation. Such tissue confirmation can be performed by either abdominal CT or ultrasound-guided FNA, ERCP-guided bile duct or pancreatic duct brushings or EUS-guided FNA.\[[@ref50]\] The value and clinical necessity of such biopsies remains controversial. In the majority of cases, these techniques are easily performed, but have variable degrees of sensitivity and specificity as discussed in the section on diagnostic criteria. Size, criteria and location criteria for the utilization of image-guided biopsy techniques are controversial, but EUS has become the dominant technique for evaluating and performing a biopsy on known or suspected pancreatic masses. Most pancreatic neoplasms are adenocarcinoma, but the differential diagnosis includes pancreatic neuroendocrine tumors, autoimmune pancreatitis, and metastatic disease (among other causes). Given the need for tissue diagnosis prior to neoadjuvant or palliative chemotherapy, FNA is almost always performed for solid pancreatic tumors. Biopsy is most commonly performed through EUS guidance or CT guidance. EUS FNA has similar, and possibly superior, sensitivity to CT guided FNA.\[[@ref51]\] There is also the possibility of an increased risk of peritoneal carcinomatosis by tumor seeding using the percutaneous approach (which may be reduced through EUS guided FNA).\[[@ref52]\] The use of EUS in staging pancreatic cancer allows for identification of resectability and FNA in the same procedure. EUS diagnosis of pancreatic masses can be limited in the setting of recent acute pancreatitis (\<4 weeks), chronic pancreatitis, a prominent ventral/dorsal split of the pancreatic head, or in diffusely infiltrating cancer (all of which distort the underlying parenchyma, which EUS relies upon to see abnormal masses through contrast between the two).\[[@ref53]\]

Techniques for the workup of solid and cystic lesions of the pancreas vary. Cysts should be aspirated with as much fluid being drawn off as possible and sent for cytologic, chemical and molecular analysis; CEA appears to be the most helpful and would be the priority when limited fluid is obtained. Multiple FNAs of solid lesions should be obtained if immediate on-site cytologic evaluation is not available. If an on-site cytopathologic evaluation is available, then intraprocedural cytologic evaluation should be performed to insure adequacy of tissue samples.

PRE-FNA REQUIREMENTS {#sec1-9}
====================

Informed consent form for pancreaticobiliary FNA {#sec2-1}
------------------------------------------------

Informed consent is the communication process between the patient and the physician that results in the patient\'s agreement to undergo a particular procedure and/or treatment.\[[@ref54][@ref55][@ref56][@ref57][@ref54][@ref59][@ref60]\] The principle of informed consent is a legal principle and based on the belief that a competent individual has the right to determine what is done to her or him.\[[@ref54][@ref55][@ref56][@ref57][@ref54][@ref59][@ref60]\] All medical care including the procuring of laboratory tests requires at least informal informed consent except when a patient is incompetent to make decisions or has abrogated that right.\[[@ref54][@ref55][@ref56][@ref57][@ref54][@ref59][@ref60]\] Legislation regulating conditions under which informed consent must be obtained vary from state to state.\[[@ref54][@ref58][@ref59]\] Due to this variability, providers including pathologists, radiologists, endoscopists and surgeons need to be familiar with the informed consent policies based on state regulations. The AMA recommends that the following be disclosed and discussed with the patient:

The patient\'s diagnosis, if knownThe nature and purpose of the proposed treatment or procedureThe risks and benefits of a proposed treatment or procedureAlternate optionsThe risk and benefits of the alternate treatment or procedureThe risks and benefits of not receiving or undergoing the treatment or procedure.

Unfortunately, informed consent procedures are imperfect.\[[@ref54][@ref55]\] Less than half of the population understands commonly utilized medical terms which limits the value to the patient of many informed consents. It is often not feasible to discuss all alternate options in the limited time available in the preprocedure setting, especially in the era of open-access radiology and open-access endoscopy.\[[@ref61][@ref62][@ref63][@ref64][@ref65]\] The use of written information supplied during the informed consent procedure may increase patient comprehension.\[[@ref66][@ref67][@ref68][@ref69]\] No matter what form informed consent takes, it must be clearly understood by the patient and adequate opportunity for patient questions must be available.\[[@ref69]\]

Informed consent recommendations {#sec2-2}
--------------------------------

Use of informed consent materials including written documents describing the FNA procedure and potential risks and complications may be consideredThe possibility of bleeding, allergic/cardiac/respiratory reaction, hemorrhage, and/or perforation should be mentionedInformation should be presented in a manner to facilitate patient understandingInformed consent should include telling the patient that the results may be non-contributory (unhelpful)Estimates of accuracy such as false negative or false positive rates are not mandatory and should be discussed only if the practitioner believes that they would facilitate patient comprehension.

INFORMATION REQUIRED ON THE REQUISITION FORM THAT ACCOMPANIES A PANCREATIC FNA REQUEST {#sec1-10}
======================================================================================

Federal regulations in the United States require that certain identifying information be provided to laboratories with all specimens submitted for laboratory testing.\[[@ref70]\] These requirements include:

Name and address of person requesting the testPatient\'s name and/or unique identifierPatient genderPatient age or date of birthName of the test to be performedSpecimen source and location, i.e., \"head of pancreas\"Date of specimen collectionAny additional relevant information (This request is usually construed to mean clinical history).

Additional relevant information which when included is helpful for specimen evaluation should be conveyed to the pathologist in the clinical or additional information section. This information may include precise site of the lesion being sampled, the tissue traversed in FNA (transgastric, transduodenal, etc.), the presence or absence of bile duct or pancreatic duct stricture, and the size of the lesion. The solid or cystic nature of the lesion should also be included in the clinical history. In cystic lesions, the configuration of the cyst, whether single or multilocular is helpful for pathologic examination. Similarly, the ultrasonographic, CT or MR characteristics of the lesion should be included as additional information, including presence of vascular or other organ invasion or known metastatic disease. History of prior malignancy should be included, as well as history of alternative diagnoses (alcoholic abuse, pancreatitis, PSC/IBD, autoimmune disease) if relevant. The occurrence of recent pancreatitis or cholangitis, and presence of a stent should also be included with relevant history, as inflammation or stent-induced atypia may need to be taken into consideration. Clinical suspicion of neuroendocrine tumor or lymphoma should be indicated, as it requires special stains/media.
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